The best thing about Pfizer’s failure with AstraZeneca

The collapse of Pfizer’s bid to take over AstraZeneca was a good day for investors, because mega-mergers usually destroy shareholder value while enriching the investment bankers, writes Matthew Lynn.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.